37619-25-3

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
1H-Benzimidazole-4-carboxylic acid, methyl ester (9CI) is used as a valuable building block for potential drug candidates due to its stability and cell membrane permeability. Its versatile properties make it a promising compound in medicinal chemistry for the development of new therapeutic agents.
Used in Antitumor Applications:
In the field of oncology, 1H-Benzimidazole-4-carboxylic acid, methyl ester (9CI) is used as an antitumor agent. It has shown potential in inhibiting the growth and progression of various types of cancer, making it a promising candidate for further research and development in cancer treatment.
Used in Neurodegenerative Disease Treatment:
1H-Benzimidazole-4-carboxylic acid, methyl ester (9CI) is also studied for its potential use in the treatment of neurodegenerative diseases. Its ability to penetrate cell membranes and interact with biological targets makes it a candidate for developing therapies to address these complex conditions.
Used in Antiviral and Antiparasitic Applications:
Furthermore, 1H-Benzimidazole-4-carboxylic acid, methyl ester (9CI) has been synthesized and studied for its potential to act as an antiviral and antiparasitic agent. Its diverse applications in infectious disease treatment highlight its potential as a versatile compound in pharmaceutical research.

InChI:InChI=1/C9H8N2O2/c1-13-9(12)6-3-2-4-7-8(6)11-5-10-7/h2-5H,1H3,(H,10,11)

Upstream product

• 122-51-0 orthoformic acid triethyl ester 
• 64-18-6 formic acid 
• 57113-91-4 methyl 3-nitroanthranilate 
• 67-56-1 methanol 
• 46006-36-4 benzimidazole-4-carboxylic acid 
• 107582-20-7 2,3-diaminobenzoic acid methyl ester 
• 149-73-5 trimethyl orthoformate 
• 603-81-6 2,3-diaminobenzoic acid 
• 606-18-8 3-nitroanthranilic acid 
• 77326-45-5 2-carbamoyl-3-nitrobenzoic acid 
• 641-70-3 3-nitrophthalic acid anhydride 

Downstream Products

• 667919-16-6 1-phenyl-1H-benzoimidazole-4-carboxylic acid methyl ester 
• 1422206-13-0 methyl 1-methyl-6-({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole-4-carboxylate 
• 1422205-93-3 methyl 6-amino-1H-benzimidazole-4-carboxylate 
• 1422205-94-4 methyl 6-({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole-4-carboxylate 
• 144876-36-8 1H-benzo[d]imidazole-4-carbaldehyde 
• 1352874-02-2 N-{4'-[3-(1H-Benzoimidazol-4-ylmethyl)-6-fluoro-2-imino-2,3-dihydro-benzoimidazol-1-yl]-5-chloro-biphenyl-2-yl}-acetamide 
• 65658-13-1 (1H-benzo[d]imidazol-4-yl)methanol 
• 132873-77-9 4-(bromomethyl)benzimidazole-1-carboxylic acid,1,1-dimethylethyl ester 

Relevant academic research and scientific papers

Benzimidazole derivative BI321 as well as preparation method and application thereof

The present invention discloses a benzimidazole derivative BI321 and a preparation method thereof. The chemical name of the benzimidazole derivative BI321 is 1-[tetrahydro-3, 4-dihydroxy-5-(hydroxymethyl) furan-2-yl]-N, N-dimethyl-1H-benzo [d] imidazole-4-carboxamide. The benzimidazole derivative and pharmaceutically acceptable salt, solvate and hydrate thereof have excellent anti-tumor in-vivo and in-vitro activity on MCF-7, SK-BR-3, HCT 116, U-118 MG, U-87 MG and MDA-MB-468, and have a relatively good application prospect in preparation of anti-tumor drugs.

Benzimidazole derivative BI361 and preparation method and application thereof

The invention discloses a benzimidazole derivative BI361 and a preparation method thereof. The chemical name of the benzimidazole derivative BI361 is {1-[tetrahydro-3, 4-dihydroxy-5-(hydroxymethyl) furan-2-yl]-1H-benzo [d] imidazol-4-yl} (piperidin-1-yl) ketone. The benzimidazole derivative and pharmaceutically acceptable salts, solvates and hydrates thereof have excellent anti-tumor in-vivo and in-vitro activity on MCF-7, SK-BR-3, HCT 116, U-118 MG, U-87 MG and MDA-MB-468, and have good application prospects in preparation of anti-tumor drugs.

Benzimidazole derivative BI293 and preparation method and application thereof

The invention discloses a benzimidazole derivative BI293 and a preparation method thereof. The chemical name of the benzimidazole derivative BI293 is 1-[(2R, 3R, 4S, 5R)-3, 4-dihydroxy-5- (hydroxymethyl) tetrahydrofuran-2-yl]-1H benzo [d] imidazole-4-formamide. The benzimidazole derivative and pharmaceutically acceptable salt, solvate and hydrate thereof have excellent anti-tumor in-vivo and in-vitro activity on MCF-7, SK-BR-3, HCT 116, U-118 MG, U-87 MG and MDA-MB-468, and have good application prospects in preparation of anti-tumor drugs.

Benzimidazole derivative BI308 as well as preparation method and application thereof

The invention discloses a benzimidazole derivative BI308 and a preparation method thereof, and the benzimidazole derivative BI308 is chemically named as methyl 1-[(2R, 3R, 4S, 5R)-3, 4-dihydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H benzo [d] imidazole-4-carboxylic ester. The benzimidazole derivative and the pharmaceutically acceptable salt, the solvate and the hydrate of the benzimidazole derivative have excellent in-vivo and in-vitro anti-tumor activity on MCF-7, SK-BR-3, HCT 116, U-118 MG, U-87 MG and MDA-MB-468, and have a relatively good application prospect in preparation of anti-tumor drugs.

IMMUNOMODULATORY COMPOUNDS

Disclosed are immunomodulatory compounds, pharmaceutical compositions containing them, and methods of making and using the compounds to treat diseases and disorders characterized by aberrant protein activity that can be targeted by cereblon.

BENZIMIDAZOLES DERIVATIVES AS ANTI-TUBERCULOSIS AGENTS

The present invention provides novel compounds of benzimidazole derivatives as anti-tubercular agents and their pharmaceutically acceptable salts for use as bactericidal therapeutics. The invention also provides a pharmaceutical composition comprising a c

Scaffold Morphing To Identify Novel DprE1 Inhibitors with Antimycobacterial Activity

We report a novel benzimidazole (BI) based DprE1 inhibitor that resulted from scaffold morphing of a 1,4-azaindole series. The clinical progression of the 1,4-azaindole series from our previous work validates the potential of exploring newer chemical enti

INDAZOLYL THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE

The invention provides indazolyl thiadiazolamines and related compounds, pharmaceutical compositions, methods of inhibiting Rho-associated protein kinase, and methods of treating inflammatory disorders, immune disorders, fibrotic disorders, and other medical disorders using such compounds. An exemplary indazolyl thiadiazolamine compound is an N-(5-[5-[(1H4ndazol-5-yl)amino]-1,3,4-thiadiazol-2-yl]pyridin-3-yl)acetamide compound.

Synthesis and pharmacological evaluation of N-benzyl substituted 4-bromo-2,5-dimethoxyphenethylamines as 5-HT2A/2C partial agonists

N-Benzyl substitution of phenethylamine 5-HT2A receptor agonists has dramatic effects on binding affinity, receptor selectivity and agonist activity. In this paper we examine how affinity for the 5-HT2A/2C receptors are influenced by N-benzyl substitution of 4-bromo-2,5-dimethoxyphenethylamine derivatives. Special attention is given to the 2′ and 3′-position of the N-benzyl as such compounds are known to be very potent. We found that substitutions in these positions are generally well tolerated. The 2′-position was further examined using a range of substituents to probe the hydrogen bonding requirements for optimal affinity and selectivity, and it was found that small changes in the ligands in this area had a profound effect on their affinities. Furthermore, two ligands that lack a 2′-benzyl substituent were also found to have high affinity contradicting previous held notions. Several high-affinity ligands were identified and assayed for functional activity at the 5-HT2A and 5-HT2C receptor, and they were generally found to be less efficacious agonists than previously reported N-benzyl phenethylamines.

Deprotection of N-benzylbenzimidazoles and N-benzylimidazoles with triethylsilane and Pd/C

The benzyl group is a protecting group for benzimidazoles and imidazoles that can survive acidic, basic, oxidizing, and reducing conditions. Deprotection, however, can require vigorous and potentially non-chemoselective methods. The triethylsilane–Pd/C reduction system is an exceptionally mild, convenient, and efficient method for deprotecting N-benzylbenzimidazoles that are unsubstituted at the 2- and 4-positions as well as suitably substituted N-benzylimidazoles.